CCK$_B$ receptor antagonist L365,260 potentiates the efficacy to and reverses chronic tolerance to electroacupuncture-induced analgesia in mice

Cheng Huang$^{a,b}$, Zhi-Ping Hu$^a$, Shao-Zu Jiang$^a$, Han-Ting Li$^a$, Ji-Sheng Han$^b$, You Wan$^{b,*}$

$^a$ Department of Physiology, Gannan Medical University, 1 Yixueyuan Road, Ganzhou 341000, PR China
$^b$ Neuroscience Research Institute and Department of Neurobiology, Key Laboratory of Neuroscience, Peking University, 38 Xue Yuan Road, Beijing 100083, PR China

Received 22 April 2006; received in revised form 15 October 2006; accepted 20 November 2006
Available online 11 December 2006

Abstract

Cholecystokinin octapeptide (CCK-8) is a physiological antagonist of endogenous opioids in the central nervous system (CNS). Our previous work has shown that CCK-8 plays an important role in the development of tolerance to morphine analgesia and electroacupuncture (EA) analgesia in the rat. The present studies were designed to examine whether the CCK$_B$ receptor is involved in the modulation of EA analgesia and the development of EA tolerance in mice. The latency to flick the tail in the radiant heat was used as index to assess the efficacy of EA analgesia. Subcutaneous (s.c.) injection of the CCK$_B$ receptor antagonist L365,260 produced a dose-dependent (0.125–2.0 mg/kg) potentiation of the analgesia induced by 100 Hz EA, with a maximal effect occurred at 0.5 mg/kg. In addition, L365,260 (0.5 mg/kg) significantly reversed chronic tolerance to 100 Hz EA in mice. These results suggest that the CCK$_B$ receptor might play a role in the tonic inhibition of 100 Hz EA-induced analgesia and in the mediation of chronic tolerance to 100 Hz EA in mice. The results opened a way for further investigation of the function of CCK-8 in pain modulation using inbred strains of mice.

© 2006 Elsevier Inc. All rights reserved.

Keywords: Cholecystokinin octapeptide; CCK-8; CCK$_B$ receptor; L365,260; Acupuncture; Analgesia; Tolerance

1. Introduction

Acupuncture has been used in China and other Asian countries for more than 2000 years. It is very effective in the treatment of many diseases including pain, and has little aversive side effects [5,11,21]. However, when acupuncture is applied for a prolonged period of time, the analgesic effects will decrease, this phenomenon is called “acupuncture tolerance” [10,12,20,24]. Our previous studies indicated that electroacupuncture (EA) produces analgesic effect through the release of endogenous opioid peptides including endorphins, enkephalins, dynorphin and endomorphin [9,13]. On the other hand, the efficacy of EA-induced analgesia depends on a functional balance between the opioid peptides and the anti-opioid peptides in the central nervous system (CNS) [10,20,26].

Many neurotransmitters and peptides, including cholecystokinin octapeptide (CCK-8), are known to be involved in acupuncture-induced analgesia and tolerance. CCK-8 is widely distributed in the central nervous system [22]. Endogenous CCK-8 has been shown to have a potent antagonistic effect on opioid antinociception [6]. CCK-8 has been shown to exert an anti-opioid effect via the activation of CCK$_B$ receptors in the CNS [9,10,19,17,26]. CCK-8 is also involved in opioid tolerance. CCK-8 was markedly increased in rat brain when morphine tolerance or EA tolerance was induced [7,9,26,27]. Both CCK$_A$ and CCK$_B$ receptor mRNA expression in the hypothalamus of rats was significantly increased in the low responders of 100 Hz EA-induced analgesia compared to high responders [16]. This result suggests that the CCK receptor seem to play a key role in determining the effectiveness of EA analgesia. Regarding the involvement of subtypes of CCK receptors in the CCK–opioid interaction, overwhelming evidence, obtained from the administration of highly selective receptor antagonists and antisense oligonucleotides in rodents, have shown that CCK$_B$ receptors mediate the anti-opioid function in the CNS [2,27].

CCK-8 and/or CCK receptors have been reported to be involved in EA analgesia and tolerance in rats and in rabbits [1,3,26]. No information is available whether the same phenomenon applies for mice. We reported in a previous study that different stains of mice with different genetic background
showed a wide variety in antinociceptive response toward EA stimulation [23]. The aim of the present study was to explore whether CCKB receptors are involved in EA analgesia and EA tolerance in mice as in the rat. L365,260, a specific CCKB receptor antagonist, was used as a tool to observe whether it could enhance the efficacy of EA analgesia and reverse the development of EA tolerance in mice.

2. Materials and methods

2.1. Animals and chemicals

Male DBA/2 mice weighing 20–25 g were provided by the Animal Department of Peking University. They were housed four per cage under natural light–dark cycles with food pellets and water ad libitum according to the University Guidelines for Animal Care and Use adapted from NIH, USA. In all studies, measures were taken to minimize pain and/or discomfort in mice. L365,260 [3R(+)-N-(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N-(3-methyl-phenyl)urea] was donated by Drs. Iversen and Freidinger of Merck Sharp and Dohme Laboratory. L365,260 was dissolved in 20% dimethylsulfoxide and 80% propylene glycol. Either different dose of L365,260 (10 mg/kg) or vehicle were injected subcutaneously (s.c.) 20 min prior to EA. All injections were in a volume of 0.1 ml/10 g body weight.

2.2. Nociceptive testing

Experiments were performed in a temperature-controlled room (22 ± 1 °C). Mice were kept in a specially designed polyethylene holder, with the hind legs and tail exposed. Nociception was assessed using the radiant heat-induced tail flick latency (TFL) as described previously [14,23]. Focused light from a projection bulb was applied to the tail 2–3 cm from the tip and the TFL was measured. The intensity of thermal stimulus was adjusted by changing the voltage of electricity to obtain a basal latency within the range of 3.5–5.5 s. To avoid tissue damage, a cut-off limit of 10 s was used. Mice were placed in the holder and inserted with acupuncture needles, and remaining in situ for 30 min prior to the assessment of the basal TFL. The mean of three consecutive measures at 5-min interval was taken as the basal TFL.

2.3. Electroacupuncture stimulation

EA was applied as reported previously [14]. The apparatus is shown in Fig. 1. The bent “L” shaped distal ends of the stainless-steel needles (0.15 mm diameter) were inserted in each hind leg, 3 mm in depth at the Zusanli acupoint (ST 36) near the knee joint and just penetrable at the Sanyinjiao acupoint (SP 6). After insertion, the needles were fixed in situ with adhesive tape. The proximal ends of the needles were connected to a Han’s Acupoint Nerve Stimulator (HANS). Square waves generated from the HANS were applied to acupoints simultaneously. The frequency was 100 Hz and the pulse width was 0.2 ms. To prevent mice from stressful response, the stimulation intensity used in the present study was not higher than 1.5 mA as described previously [14]. During the experiment, mice kept quite and did not show struggling and other stressful responses. The frequency was 100 Hz and the pulse width was 0.2 ms. To prevent mice from stressful response, the stimulation intensity used in the present study was not higher than 1.5 mA as described previously [14]. During the experiment, mice kept quite and did not show struggling and other stressful responses. The intensity of stimulation (0.5–1.0–1.5 mA) was increased in a stepwise manner mice kept quite and did not show struggling and other stressful responses. The frequency was 100 Hz and the pulse width was 0.2 ms. To prevent mice from stressful response, the stimulation intensity used in the present study was not higher than 1.5 mA as described previously [14]. During the experiment, mice kept quite and did not show struggling and other stressful responses. The intensity of stimulation (0.5–1.0–1.5 mA) was increased in a stepwise manner mice kept quite and did not show struggling and other stressful responses.

2.4. Electroacupuncture tolerance

Chronic tolerance to 100 Hz EA was developed according to our previous report [12]. EA was applied to mice once daily, 30 min/session, for 6 days consecutively. The basal TFL was examined before EA administration in each day. The thermal latency was examined at the end of EA each day to evaluate the EA-induced analgesic effect. The analgesic effect decreased along with the increase of number of EA applications, indicating the development of chronic tolerance to EA [20].

2.5. Statistical analysis

Data were expressed as mean ± S.E.M. Group difference was analyzed by one-way analyses of variance (ANOVA) followed by Newman-Keuls post hoc test. P < 0.05 was used to determine a significant difference.

3. Results

One week before the experiment with L365,260, 160 mice were divided into three groups according to the analgesic effect induced by EA. The 100 Hz EA was delivered to mice for 30 min. Those mice with an over 50% increase of TFL were classified as high responders (n = 45); those lower than 20% as low responders (n = 58), and those intercalated between 20% and 50% were discarded (n = 57).

3.1. Dose–response curve of L365,260 on 100 Hz EA-induced analgesia in low responder mice

To observe the effect of L365,260 on basal thermal latency, TFL was measured at 10-min interval for a total of 60 min after injection. L365,260, ranged from 0.125, 0.25, 0.5, 1.0 to 2.0 mg/kg was used. The TFL fluctuated within the range of 0–4 ± 2.4% in all groups (9–10 per group), suggesting that s.c. L365,260 produced neither antinociception nor hyperalgesia in mice (data not shown).

In order to explore whether the low responders can be changed into high responders, we observed the effect of s.c. L365,260 on 100 Hz EA-induced analgesia. Fifty-eight low responder mice were randomly divided into six groups (9–10 per group) and given s.c. injection of vehicle or L365,260 at
Discussions

In order to explore whether the EA tolerance can be reversed by the CCKB antagonist L365,260, mice were made tolerant to EA following the procedure stated in the methodology. As shown in Fig. 3, the analgesic effect induced by 100 Hz EA decreased gradually from day 1 to 6 ($P < 0.05$), indicating the development of chronic tolerance to EA. The mice were then randomly divided into 2 groups of 10 each. On day 7, another session of 100 Hz EA was applied 20 min after s.c. injection of either L365,260 (0.5 mg/kg) or vehicle. The results are shown in Fig. 2. The EA analgesic effects in the L365,260 group (39.4 ± 7.0%) were significantly higher than those in the vehicle group (13.7 ± 1.8%) ($P < 0.01$).

3.2. Reversal effect of L365,260 on chronic 100 Hz EA tolerance

In order to explore whether the EA tolerance can be reversed by the CCKB antagonist L365,260, mice were made tolerant to EA following the procedure stated in the methodology. As shown in Fig. 3, the analgesic effect induced by 100 Hz EA decreased gradually from day 1 to 6 ($P < 0.05$), indicating the development of chronic tolerance to EA. The mice were then randomly divided into 2 groups of 10 each. On day 7, another session of 100 Hz EA was applied 20 min after s.c. injection of either L365,260 (0.5 mg/kg) or vehicle. The results are shown in Fig. 2. The EA analgesic effects in the L365,260 group (39.4 ± 7.0%) were significantly higher than those in the vehicle group (13.7 ± 1.8%) ($P < 0.01$).

4. Discussion

The main finding of the present study is that CCKB receptor antagonist L365,260 can potentiate 100 Hz EA-induced analgesia and reverse chronic tolerance to 100 Hz EA in mice. This suggests that endogenous CCKB receptors might be involved in the modulation of EA analgesia and EA chronic tolerance in mice.

The interaction between CCK-8 and opioids was first reported by Ito et al. [15], and CCK-8 has been shown to possess potent anti-opioid activities in the CNS [6]. Faris et al. observed that intracerebroventricular (i.c.v.) injection of CCK-8 suppressed antinociception induced by β-endorphin, and that CCK given i.p. prior to systemic morphine application significantly reduced the analgesic effect of morphine [7]. The antagonism of CCK-8 to morphine-induced antinociception was dose-dependent [25]. Proglumide, a nonselective CCK antagonist, was also reported to potentiate morphine induced antinociception without causing antinociception by itself [18,25]. These results suggest that endogenous CCK-8 attenuates antinociception induced by the administration of opioids, thus acting as a negative feedback modulator. Regarding the involvement of subtypes of CCK-8 receptors in the CCK–opioid interaction, overwhelming evidence obtained from the administration of highly selective receptor antagonists and antisense oligonucleotides in rodents have shown that CCKB receptors mediate the anti-opioid function of CCK-8 in the CNS [2,27]. Reports also show that CCK-8 might be involved in the EA-induced analgesia. Han et al. [9] measured the CCK-8 release in the rat spinal perfusate and found that those rats, showing a significant CCK-8 increase during 100 Hz EA, were low responders (i.e. exhibiting weaker EA analgesia), whereas rats, showing little CCK-8 increase, were high responders (i.e. exhibiting stronger EA analgesia) [8]. Tang et al. found that the CCK-8 release was significantly higher in the low responder rats compared to high responders in the midbrain periaqueductal gray (PAG), and i.c.v. injection of antisense oligonucleotides to CCK-8 mRNA enhanced 100 Hz EA-induced analgesia and convert low responder rats into high responders for EA analgesia [19]. Chen et al. demonstrated that i.c.v. injection of L365,260 into the PAG significantly increased the analgesic effect induced by 100 Hz EA in rats [3]. In the present study, we used L365,260, a highly specific CCKB receptor antagonist, to study the anti-opioid effect of CCK against 100 Hz EA in mice. As shown in Fig. 2, L365,265 can potentiate the analgesic effect induced by 100 Hz EA in low responder mice, suggesting that low responders have been changed to...
higher responders. This finding has shown that CCK_{B} receptors in mice is involved in the anti-opioid effect in antinoceception. The bell shape of the dose–response curve (Fig. 2) is very similar to that observed in the experiment showing the potentiation of 100 Hz EA-induced analgesia in mice by nocistatin, another endogenous antiopioid peptide [12]. Given that the opioid receptor and CCK receptor are existing in one and the same neuron [17], the kinetics of the physiological interaction between the opioid receptor and the receptors of CCK/nocistatin (regarded as physiological opioid antagonists) deserve further investigation.

As shown in Fig. 3, mice, given daily 100 Hz EA for 6 consecutive days, developed chronic tolerance to 100 Hz EA, and that L365,260 can reverse the chronic 100 Hz EA tolerance. As mentioned above, EA can release opioid peptides in the CNS to produce analgesia [9]. A high level of CCK-8 in the CNS may exert a suppressive effect on EA-induced analgesia by antagonizing the endogenous opioids [15]. A number of studies support this viewpoint. For example, Zhou et al. [26,27] measured the content of CCK-8-immunoreactivity (CCK-ir) in rat spinal fusate, and found that CCK-8 increased significantly in rats made tolerant to EA. Our previous works have shown that L365,260 can delay the development of EA tolerance in rats, and antsense oligonucleotides to CCK mRNA can also delay the development of tolerance elicited by prolonged 100 Hz EA stimulation [4,19]. The present study further suggests that the endogenous release of CCK-8 is also involved in 100 Hz EA tolerance in mice, as in rats [10,16,19,26].

When EA is applied for a prolonged period of time such as in the treatment of chronic pain, the analgesic effects will decrease. The current results may help in finding a useful method to improve the therapeutic effects of EA in the treatment of chronic diseases when “EA tolerance” occurs [9,12,20]. In addition, this study will redound to further study on EA using inbred strains of mice.

Conflict of interest

There is no financial or other conflict of interest with any person or institution regarding publication of this manuscript.

Acknowledgements

This work was supported by the National Natural Science Foundation of China (30560145, 30570566) and Beijing Natural Science Foundation (7052039). Authors thank Ms. Catherine Whitman in University College of Physicians & Surgeons for the preparation of the manuscript. Authors also thank Dr. Xiao-Hong Chen at Temple University for her critical review of this manuscript.

References


[24] Q. Wang, L. Mao, J.S. Han, Analgesic electrical stimulation of the hypothalamic arcuate nucleus: tolerance and its cross-tolerance to 2 Hz or 100 Hz electroacupuncture, Brain Res. 518 (1990) 40–46.

